HP3JC Motoman Robotic Arm and CombiFlash Automated Chromatography Systems

描述（由申请人提供）：神经退行性疾病药物发现实验室（LDDN）是一个与全国各地的实验室合作进行高通量筛选和药物化学项目的中心，重点是神经退行性疾病的药物发现。本提案的目的是：1)要求升级我们的自动化集成机器人系统，用他们新的Motoman机器人手臂取代Beckman Coulter不再支持的Orca机器人手臂。这种新的手臂和现有设备的集成将大大提高我们的自动化能力，其速度更快，能力更强。2)申请两套CombiFlash Rf-75自动闪光色谱系统，以取代现有老化和失效的色谱系统。LDDN每年有5个新的合作项目得到NINDS U24资助，用于高通量筛选和药物化学的国家神经退行性疾病药物发现中心（NCDDN）计划。此外，每年5-10个由其他NIH和基金会资助的高通量筛选合作项目也使用该自动化设备，并将大大受益。使用该设备的长期目标是促进识别神经退行性疾病和其他疾病的新疗法。我们还确定了可以被研究界使用的新工具化合物。

DESCRIPTION (provided by applicant): The Laboratory for Drug Discovery for Neurodegeneration (LDDN) is a center that collaborates with laboratories from around the country for high throughput screening and medicinal chemistry projects for drug discovery with a focus on neurodegenerative diseases. The purpose of this proposal is: 1) to request an upgrade of our automated integrated robotic system to replace a robotic Orca arm that is no longer supported by Beckman Coulter with their new Motoman robotic arm. This new arm and integration with existing equipment will greatly improve our automation capabilities with its much higher speed and greater capabilities. 2) to request two CombiFlash Rf-75 Automated Flash Chromatography Systems to replace existing chromatography systems that are old and failing. Five new collaborative projects per year at LDDN are supported through a NINDS U24 grant National Center for Drug Discovery for Neurodegeneration (NCDDN) program for high throughput screening and medicinal chemistry. In addition, 5-10 collaborative projects per year for high throughput screening that are supported through other NIH and foundation grants also use this automation equipment and will greatly benefit. Long term objective for use of this requested equipment is to facilitate identification of new therapeutics for neurodegenerative and other diseases. We also identify new tool compounds that can be used by the research community. PUBLIC HEALTH RELEVANCE: We are focused on developing novel therapeutics for neurodegenerative and other diseases. An upgraded automated and integrated robotics system will allow for the initial identification of compounds that can be further optimized to be a drug candidate and the automated compound purification systems allow for more efficient compound synthesis during the medicinal chemistry optimization phase of a project. Requested equipment is to replace old and obsolete existing equipment at our facility.